NXL

Nexalin Technology, Inc. (NXL) - Q2 2025 Filing Summary

Business Context and Reporting Period

This summary covers the Unaudited Condensed Consolidated Financial Statements for Nexalin Technology, Inc. for the quarterly period ended June 30, 2025. Nexalin is a medical device company developing non-invasive neurostimulation products (Gen-1, Gen-2 SYNC, and Gen-3 HALO) to treat anxiety, insomnia, and depression. The company is classified as a Smaller Reporting Company and an Emerging Growth Company. As of August 5, 2025, there were 17,417,929 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q2 2025 revenue increased 163% compared to Q2 2024, driven primarily by a large shipment of equipment boards to China. YTD revenue increased 6%.
• Margin Compression: Gross margin decreased from 84% in YTD 2024 to 67% in YTD 2025. This shift is attributed to a change in revenue mix, with a higher proportion of lower-margin equipment sales compared to high-margin licensing fees in the prior year.
• Operating Expenses: Total operating expenses increased 51% YTD 2025 vs. 2024. Key drivers include:
  • Stock-Based Compensation: Increased by approximately $740,000 YTD, largely due to executive grants and consultant awards.
  • R&D Expenses: Increased 130% YTD, driven by clinical trial costs (UCSD study) and development of the Gen-3 HALO app and device.
  • Professional Fees: Increased 17% YTD due to costs associated with the recent capital raise and registration statements.
• Capital Raise: In Q2 2025, the company completed a public offering of 4,090,000 shares, generating net proceeds of approximately $4.65 million.

Outlook, Risks, and Contingencies

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next twelve months. Despite a working capital surplus, the company expects to continue incurring operating losses and negative cash flows. Continued operations depend on successful revenue generation from the China joint venture, FDA approvals for Gen-2/Gen-3 devices, and the ability to raise additional capital.
• Regulatory Status:
  • Gen-1: Marketing for new sales in the U.S. is paused pending FDA reclassification discussions.
  • Gen-2 SYNC & Gen-3 HALO: Currently in the FDA Q-submission process. Clinical trials are planned for the U.S., Brazil, and China throughout 2025.
  • International: Gen-2 is approved for sale in China (NMPA) and Brazil. Conditional approval was granted in Oman.
• Legal Proceedings:
  • Sarah Veltz v. Nexalin: A lawsuit regarding unpaid wages and sexual harassment was settled in May 2025 for a confidential amount; the case was dismissed.
  • EDD Dispute: The company is in settlement discussions with the California Employment Development Department regarding worker classification. A liability of $40,000 has been accrued.
• Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and IT controls. Disclosure controls were deemed ineffective as of June 30, 2025.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $5.8M in liquid assets (cash + short-term investments) against the projected burn rate, given the explicit "substantial doubt" going concern disclosure.
• Revenue Concentration: Note that two customers accounted for 85% of Q2 2025 revenue, and three customers accounted for 71% of YTD revenue. Assess the risk of losing these key accounts.
• FDA Timeline: Monitor the progress of the Q-submission process for Gen-2 and Gen-3 devices, as U.S. commercialization is contingent on FDA clearance.
• Stock-Based Compensation: Review the impact of the $1.2M in stock-based compensation expense YTD on future cash burn and potential dilution.
• Internal Control Remediation: Track the company's progress in remedying the identified material weaknesses in financial reporting controls.